GENE
Price:
$0.885
Market Cap:
$9.71M
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops othe...[Read more]
Industry
Medical - Diagnostics & Research
IPO Date
2005-09-06
Stock Exchange
NASDAQ
Ticker
GENE
According to Genetic Technologies Limited’s latest financial reports and current stock price. The company's current PE Ratio is -5.90. This represents a change of -70.93% compared to the average of -20.30 of the last 4 quarters.
The mean historical PE Ratio of Genetic Technologies Limited over the last ten years is -76.88. The current -5.90 PE Ratio has changed 667.40% with respect to the historical average. Over the past ten years (40 quarters), GENE's PE Ratio was at its highest in in the March 2024 quarter at 0. The PE Ratio was at its lowest in in the March 2021 quarter at -339.24.
Average
-76.88
Median
-37.48
Minimum
-335.75
Maximum
-10.55
Discovering the peaks and valleys of Genetic Technologies Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 266.46%
Maximum Annual PE Ratio = -10.55
Minimum Annual Increase = -67.65%
Minimum Annual PE Ratio = -335.75
Year | PE Ratio | Change |
---|---|---|
2024 | -21.22 | -60.50% |
2023 | -53.73 | -50.53% |
2022 | -108.62 | -67.65% |
2021 | -335.75 | 208.50% |
2020 | -108.83 | 49.55% |
2019 | -72.78 | 266.46% |
2018 | -19.86 | 88.25% |
2017 | -10.55 | -48.11% |
2016 | -20.33 | 18.50% |
2015 | -17.16 | 50.68% |
The current PE Ratio of Genetic Technologies Limited (GENE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-61.19
5-year avg
-125.63
10-year avg
-76.88
Genetic Technologies Limited’s PE Ratio is less than Biocept, Inc. (-0.02), less than T2 Biosystems, Inc. (-0.86), less than HTG Molecular Diagnostics, Inc. (-0.07), less than Intelligent Bio Solutions Inc. (-0.33), less than Interpace Biosciences, Inc. (2.52), less than bioAffinity Technologies, Inc. (-1.72), less than SeqLL Inc. (-3.16), less than Agilent Technologies, Inc. (28.16), less than Sera Prognostics, Inc. (0), greater than Precipio, Inc. (-7.57), less than MDxHealth SA (-2.37), less than null (-1.89),
Company | PE Ratio | Market cap |
---|---|---|
-0.02 | $0 | |
-0.86 | $51.57M | |
-0.07 | $1.06M | |
-0.33 | $4.92M | |
2.52 | $7.10M | |
-1.72 | $17.81M | |
-3.16 | $0 | |
28.16 | $39.42B | |
0 | $234.91M | |
-7.57 | $9.17M | |
-2.37 | $77.23M | |
-1.89 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genetic Technologies Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Genetic Technologies Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Genetic Technologies Limited's PE Ratio?
How is the PE Ratio calculated for Genetic Technologies Limited (GENE)?
What is the highest PE Ratio for Genetic Technologies Limited (GENE)?
What is the 3-year average PE Ratio for Genetic Technologies Limited (GENE)?
What is the 5-year average PE Ratio for Genetic Technologies Limited (GENE)?
How does the current PE Ratio for Genetic Technologies Limited (GENE) compare to its historical average?